perfluoro-N-cyclohexylpiperidine | 60234-15-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: perfluoro-N-cyclohexylpiperidine
• 英文别名: N-(F-cyclohexyl)-F-piperidine；Perfluoro(1-cyclohexylpiperidine)；2,2,3,3,4,4,5,5,6,6-decafluoro-1-(1,2,2,3,3,4,4,5,5,6,6-undecafluorocyclohexyl)piperidine
• CAS: 60234-15-3
• 化学式: C₁₁F₂₁N
• 分子量: 545.094
• InChiKey: OIRQPKJKSXGLIE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  33
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  22

反应信息

• 作为反应物：
  描述：

  perfluoro-N-cyclohexylpiperidine 在 五氟化锑 作用下， 反应 2.0h， 以72%的产率得到2,2,3,3,4,4,5,5,5-Nonafluoro-N-(1,2,2,3,3,4,4,5,5,6,6-undecafluoro-cyclohexyl)-pentanimidoyl fluoride
  参考文献：
  名称：

  Isomerization of perfluorinated cyclic amines under the action of antimony pentafluoride

  摘要：

  DOI：

  10.1007/bf00958050
• 作为产物：
  描述：

  1-环己基哌啶 生成 perfluoro-N-cyclohexylpiperidine
  参考文献：
  名称：

  ONO, TAIZO;INOUE, YOSHIHISA;ARAKAWA, YOSHIO;NAITO, YOUICHIRO;FUKAYA, CHIK+, J. FLUOR. CHEM., 43,(1989) N, C. 67-85

  摘要：

  DOI：

文献信息

• Synthesis of perfluorochemicals for use as blood substitutes. Part IV. Electrochemical fluorination of N-cycloalkyl-pyrrolidines and -piperidines
  作者：Taizo Ono、Yoshihisa Inoue、Yoshio Arakawa、Youichiro Naito、Chikara Fukaya、Kouichi Yamanouchi、Kazumasa Yokoyama

  DOI：10.1016/s0022-1139(00)81637-1

  日期：1989.4

  Electrochemical fluorination of N-cyclopentylpyrrolidine gave the corresponding F-amine together with a ring-opened compound N-(F-pentyI)-F-pyrrolidine in the ratio of 1 to 1, in 55% yield. N-cyclohexylpyrrolidine, N-cyclopentylpiperidine, and N-cyclohexylpiperidine were also eletrochemically fluorinated in the same manner to give the corresponding F-amines, their isomers with rearranged structures

  N-环戊基吡咯烷的电化学氟化以1∶1的比例得到相应的F-胺和开环的化合物N-（F-pentyI）-F-吡咯烷，产率为55％。N-环己基吡咯烷，N-环戊基哌啶和N-环己基哌啶也以相同的方式进行电子氟化，得到相应的F-胺，其重排结构的异构体和开环的胺，比率为-4：2：1 ，和2：1：1分别以51％至53％的收率。提供了支持的光谱数据。
• PERFLUOROCARBON GAS TRANSFERRING EMULSION FOR MEDICO-BIOLOGICAL USE, THE COMPOSITION AND THE PRODUCTION METHOD THEREOF A MEDICINAL AGENT
  申请人：Vorobyev, Sergey Ivanovich

  公开号：EP2005948A2

  公开（公告）日：2008-12-24

  The invention belongs to medicobiological industry and refers to the composition, method of production and use of the means, based on perfluorocarbon emulsions, intended as the blood substitute means and other remedies. The essence of invention consists in creation of method and composition made from the mixture of two perfluorocarbons: fast eliminated (Sv-syu) and (or) slowly eliminated (Sc-sp), as perfluorodecaline (PFD) / perfluoromethyl-cyclo-hexylpiperidine (PFMCP), or PFD/perfluorotributylamine (PFTBA), or perfluorooctylbromide (PFOB)/PFMCP, or PFOB/PFTBA, or PFOB/PFD, or PFMCP/PFTBA in ratio from 1/1 to 10/10, respectively; or a mixture of three perfluorocarbons: two are fast eliminated (C8-C10) and one is slowly eliminated (C11-C12), or of one fast eliminated (C8-C10) and two slowly eliminated (C11-C12), as PFOB/PFD/PFMCP, or PFOB/PFD/PFTBA, or PFOB/PFMCT/PFTBA, or PFD/PFMCP/PFTBA in ratio from 1/1/1 to 10/10/10, respectively; or a mixture of four perfluorocarbons: two of them are fast eliminated (C8-C10) and two slowly eliminated (C11-C12) PFOB/PFD/PFMCP/PFTBA in ratio from 1/1/1/1 to 10/10/10/10, respectively; a mixture of perfluorocarbons in emulsion from 1% (0,5 vol.%) to 100% (50 vol. %) with average particle size 30-80 nm, is emulsified by proxanol-268 from 0,2% to 20% with molecular weight 6-12 thousand Da, has acceptable electrolytic solution.

  本发明属于医药生物行业，涉及以全氟碳化物乳液为基础的成分、生产方法和使用方 法，旨在用作血液替代品和其他疗法。本发明的精髓在于利用两种全氟化碳的混合物制造方法和组合物：快速消除型（Sv-syu）和（或）缓慢消除型（Sc-sp）全氟萘烷（PFD）/全氟甲基环己基哌啶（PFMCP），或全氟萘烷/全氟三丁胺（PFTBA），或全氟溴化辛烷（PFOB）/PFMCP，或 PFOB/PFTBA，或 PFOB/PFD，或 PFMCP/PFTBA，其比例分别为 1/1 至 10/10；或三种全氟化碳的混合物：两种快速消除（C8-C10）和一种缓慢消除（C11-C12）的混合物，或一种快速消除（C8-C10）和两种缓慢消除（C11-C12）的混合物，如 PFOB/PFD/PFMCP，或 PFOB/PFD/PFTBA，或 PFOB/PFMCT/PFTBA，或 PFD/PFMCP/PFTBA，比例分别为 1/1/1 至 10/10/10；或四种全氟化碳的混合物：PFOB/PFD/PFMCP/PFTBA，比例分别为 1/1/1/1 至 10/10/10；1%（0.5 Vol.%）至 100%（50 体积%）的全氟化碳乳液混合物，其平均粒径为 30-80 纳米，由分子量为 6-12 千 Da 的 0.2% 至 20% 的丙三醇-268 乳化，具有可接受的电解溶液。
• PETROV, V. A.;KUNANETS, V. K.;MAKAROV, K. N.;GERMAN, L. S., IZV. AN CCCP. CEP. XIM.,(1989) N, S. 646-649
  作者：PETROV, V. A.、KUNANETS, V. K.、MAKAROV, K. N.、GERMAN, L. S.

  DOI：——

  日期：——
• Verfahren zur Herstellung perfluorierter heterocyclischer Verbindungen und nach diesem Verfahren hergestellte Verbindungen
  申请人：Kali-Chemie Aktiengesellschaft

  公开号：EP0415264B1

  公开（公告）日：1994-06-29
• Medical emulsion of perfluororganic compounds and method for the production thereof
  申请人：Kuznetsova Nikolaievna Irina

  公开号：US20070197475A1

  公开（公告）日：2007-08-23

  Medicine, in particular medications for treating blood losses, hypoxic and ishemic states, for improving a blood oxygen supply and for preserving isolated perfused organs and tissues. The inventive medical emulsion of perfluororganic compounds includes rapidly excretable perfluororganic compounds such as perfluordecalin, perfluoractilbromide, a perfluoroganic additive embodied in the form of a mixture of perfluorinated tertiary amines and phospholipids in the form of a water-salt dispersion. The perfluordecalin and perfluoractilbromide are contained in the composition of the rapidly excretable perfluororganic compounds at a ratio ranging from 10:1 to 1:10. The mixture of perfluorinated tertiary amines is embodied in the form of the mixture of perfluorotpripropylamine and the co-products thereof: cis- and trans-isomers perfluor-1-propyl 3,4-dimethylpirrolidone and perfluor-1-propyl-4-methhylpiperidine. The inventive method for producing the emulsion includes producing the water-salt dispersion of phospholipids, in homogenizing the perfluororganic compounds therein at a high pressure and in sterilization of the final emulsion. The storage life of the inventive emulsion in the unfrozen state thereof at a temperature of +4° C. is equal to at least 6 months during which the biocompatibility of the emulsion with a biological medium (blood, plasma or serum) is preserved.